-

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this with unparalleled mass resolution (>10M) and sub-parts-per-million mass accuracy, plus isotope fine structure identification-confirmation, which enables the most confident identification of molecular species in ultra-complex mixtures.

As the global transition to more renewable energy accelerates, researchers face the challenge of analyzing ultra-high chemical complexity. The timsMRMS offers unprecedented capabilities for two vital areas in energy technology—renewable energy and energy storage.

  • Next-Gen Lithium Batteries: The timsMRMS enables ultra-high-confidence molecular characterization of electrolyte formulations, solid-electrolyte interphase (SEI) degradation, and molecular changes during charge-discharge cycles of lithium-ion batteries. This allows materials scientists to better understand and control the chemical mechanisms that dictate battery lifespan, safety, and energy density.
  • Advanced Bio-oils & Biofuels: By providing ultra-high-resolution clarity into molecular formulae determination and compound classes, the timsMRMS empowers researchers to address the chemical diversity of pyrolysis and biomass-derived oils, streamlining the development of sustainable, low-carbon transportation fuels.

“Many application areas in energy research present extreme levels of chemical diversity that are incredibly challenging. This has necessitated new analytical capabilities that go beyond traditional LC-MS limits,” said Dr. Paul Speir, Senior Vice President, Global MRMS Business with Bruker. “With the timsMRMS, we are equipping energy researchers with a complete unique tool that provides greater clarity and confidence in characterizing the extreme chemical complexity of next-generation batteries and alternative fuels.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Media Contact
Nora Williams
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: nora.williams@bruker.com

Investor Relations Contact
Joe Kostka
Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact
Nora Williams
Bruker Daltonics Marketing Communications
T: +49 (421) 2205-2843
E: nora.williams@bruker.com

Investor Relations Contact
Joe Kostka
Director, Investor Relations
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A...

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei...

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

SINGAPORE--(BUSINESS WIRE)--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis...
Back to Newsroom